管理血友病A/B患者相关临床条件的管理
Massimo Morfini1, Jacopo Agnelli Giacchiello2, Erminia Baldacci3
1Italian Association of Haemophilia Centers (AICE), 21121 Milan, Italy.
Hematology reports
|June 27, 2023
概括
这一共识审查强调了最佳的血友病A和B治疗策略,包括预防和外科替代疗法. 它强调延长半衰期因子缩物,并解决抑制剂管理,以改善患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 对血友病A和B患者当前的替代疗法的审查.
- 专注于使用连续输液或注射八号因子 (FVIII) 缩剂的手术管理.
- 讨论副作用,包括抑制剂的发展和血栓栓塞并发症.
研究的目的:
- 审查和讨论血友病替代疗法的关键问题.
- 为了比较持续输液 (CI) 与玻尿酸注射 (BI) 在严重血友病A的手术过程中.
- 评估血友病A和B患者的预防策略和结果,包括那些使用抑制剂的患者.
主要方法:
- 意大利9个血友病中心的医疗主任参加了共识会议.
- 对替代疗法选择的审查,包括标准和延长半衰期的第八因子 (FVIII) 和第九因子 (FIX) 缩剂.
- 讨论副作用,抑制剂的发展,血栓栓塞风险和药物动力学关系.
主要成果:
- 年轻重型血友病A患者可以从预防中受益 (2-3次/周) 标准半衰期 (SHL) rFVIII.
- 严重的B型血友病患者可能具有不太严重的表型,并受益于每周使用SHL rFIX缩剂的预防.
- 血友病B患者表现出独特的FIX药理动力学,可能是由于误解突变,使每周预防和改善生活质量.
结论:
- 优化的替代疗法,包括预防和手术管理,对于改善血友病患者的治疗结果至关重要.
- 延长半衰期的缩剂和量身定制的预防方案提高了生活质量,降低了治疗负担.
- 了解基因型-药物动力学关系有助于个性化血友病治疗策略.
相关概念视频
Disorders of Hemostasis
1.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K
Venous Thrombosis III: Interprofessional Care
11
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
11
Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
Venous Thrombosis IV: Nursing Management
15
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
15
Esophageal Varices-II: Clinical Features and Management
99
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
99
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K


